Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

| More on:
An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor interest in ASX healthcare stocks has climbed recently. The S&P/ASX 200 Healthcare Index (ASX: XHJ) dropped overall in FY25 but appears to have made some recovery so far in July.

As of lunchtime today, the index is 0.89% higher and has climbed 1.28% over the past five days. For the year to date, the index is 9.26% higher.

And continued momentum and strong potential upside for one ASX healthcare stock could drive the sector higher.

Summerset Group Holdings Ltd (ASX: SNZ) shares are flat at $11.00 as of midday today but have jumped 30.49% over the year. Over the past three months, the New Zealand retirement village developer and operator's share price has climbed 11.22%.

Here's what Macquarie Group Ltd (ASX: MQG) thinks of the stock.

Macquarie revises Summerset Group's target price

Macquarie maintains its outperform rating on Summerset Group and has raised its target price to NZ$15.75, up from NZ$15.35. As of midday today, the company's shares are trading at NZ$12.02.

The revised target price represents a potential 28% upside for the stock.

The company is dual-listed on the ASX and the NZX, which means local Australian investors could also benefit from any potential upside.

In a note to investors, the broker said the company's new sales reached a record volume in Q2 2025, up 42% compared with the previous corresponding period, and 68% higher than Q1.

Total sales for the first half of 2025 are 22% higher period-on-period, making it a record half-yearly result for the business. 

Summerset Group has seen "road-based improvement in sales and noted uncontracted new stock decreased 6% in the period and contracted stock increased by 50%."

"Australia saw 9 sales over the period, in line with FY24 contracts."

The company's resales volumes also meant it achieved the best Q2 on record and the second-best quarter overall. 

"A combination of offering, improved housing market, competitor disruptions and sales team effectiveness is underpinning strong sales and contracting will drive 2H25 growth. Upside risk to FY25 earnings is emerging, while SUM's overall growth outlook remains attractive," the broker said in its investor note. 

"Key risks include quantum and speed of improvement in housing market conditions, and associated impact on sales including St Johns. Success and speed of ramp-up in Australia is a key driver of growth in the medium to long term."

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Why are Mesoblast shares jumping 10% to a 52-week high?

This biotech is hitting new highs on Friday. Let's find out why.

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Ansell shares tumble to a 3-month low. Is this a buying opportunity?

Ansell shares have slid to a 3-month low. Could oversold signals point to a buying opportunity for long-term investors?

Read more »

Female scientist working in a laboratory.
Healthcare Shares

These three biotechs show how the sector can produce huge outsized gains, but are they still good value?

These drug developers' shares are trading near 12-month highs.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

This biotech is approaching 20-bagger status within a year and the good news continues to come

This company has just won approval to go ahead with a key clinical trial.

Read more »

An investor sits at a table in front of her laptop with a party hat on her head and a cake next to her symbolising new year's eve but the 4DS Memory share price is plunging so she looks very disappointed and depressed
Healthcare Shares

$5 billion ASX 200 healthcare stock tumbling on CEO exit

Investors are bidding down the ASX 200 healthcare giant on Thursday. Let’s see why.

Read more »

woman testing substance in laboratory dish, csl share price
Share Market News

After a 73% surge this ASX healthcare share looks far from done

Brokers are upbeat, and some see possible gains of 90% in 2026.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which biotech's shares are surging higher on US patent news?

Investors like what they see from this drug company.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Read more »